Weekly Sepsis Research Analysis
This week’s sepsis literature highlights three high-impact directions: precision dosing for beta‑lactams during renal replacement therapy with externally validated nomograms to improve PK/PD target attainment; novel immunomodulation targeting NETosis (a humanized anti‑CitH3 antibody) with a biomarker-defined therapeutic window showing preclinical reductions in mortality and lung injury; and mechanistic/therapeutic work on post‑sepsis muscle mitochondrial/autophagy dysfunction reversible by uroli
Summary
This week’s sepsis literature highlights three high-impact directions: precision dosing for beta‑lactams during renal replacement therapy with externally validated nomograms to improve PK/PD target attainment; novel immunomodulation targeting NETosis (a humanized anti‑CitH3 antibody) with a biomarker-defined therapeutic window showing preclinical reductions in mortality and lung injury; and mechanistic/therapeutic work on post‑sepsis muscle mitochondrial/autophagy dysfunction reversible by urolithin A. Across the week, advances in rapid diagnostics, multi-omic prognostic classifiers, and host‑directed strategies were recurrent and clinically actionable.
Selected Articles
1. Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy.
A prospective, multinational PK study (n=300 across 12 countries) developed and externally validated population PK models for meropenem and piperacillin/tazobactam during multiple RRT modalities. Monte Carlo simulations showed dosing needs vary by urine output and RRT intensity/duration; extended or continuous infusions improved unbound PK/PD target attainment and allowed lower daily doses. Validated nomograms were provided for bedside dosing in Enterobacterales and Pseudomonas targets.
Impact: Fills a critical knowledge gap for two cornerstone antipseudomonal beta‑lactams in RRT by delivering externally validated nomograms and practical infusion strategies that improve PK/PD attainment.
Clinical Implications: Adopt extended/continuous infusion strategies guided by the provided nomograms accounting for urine output and RRT settings; implement therapeutic drug monitoring to individualize dosing and test impact on clinical outcomes in prospective trials.
Key Findings
- Population PK models from 300 patients with external validation (mean prediction errors: −5.2% meropenem; −16.9% piperacillin).
- Dosing requirements vary significantly with urine output and RRT intensity/duration; extended/continuous infusions improved time > MIC attainment.
- Nomograms provided for different RRT modalities and PK/PD targets against Enterobacterales and P. aeruginosa.
2. A citrullinated histone H3 monoclonal antibody for immune modulation in sepsis.
A humanized monoclonal antibody against citrullinated histone H3 (hCitH3‑mAb) reduced cytokine release, mortality, and acute lung injury in multiple murine sepsis models (LPS and Pseudomonas aeruginosa) while enhancing bacterial phagocytosis. Investigators used pre‑equilibrium digital ELISA to define an optimal therapeutic window and identified TLR2 activation in macrophages as a CitH3‑driven mechanism.
Impact: First‑in‑class immunomodulatory approach that links a measurable circulating biomarker (CitH3) to therapy timing and demonstrates survival/organ benefit in preclinical sepsis models — a clear translational trajectory.
Clinical Implications: Supports early development of biomarker‑guided first‑in‑human trials of anti‑CitH3 for hyperinflammatory sepsis phenotypes and suggests potential to combine with antibiotics to reduce organ injury.
Key Findings
- hCitH3‑mAb reduced cytokine levels, acute lung injury and mortality in LPS and P. aeruginosa murine models.
- PEdELISA defined an optimal therapeutic window; CitH3 activates macrophage TLR2 signaling linking NETosis products to innate immune amplification.
3. Sepsis Induces Long-Term Muscle and Mitochondrial Dysfunction due to Autophagy Disruption Amenable by Urolithin A.
Integrated human longitudinal transcriptomics and mechanistic mouse studies show persistent mitochondrial pathway dysregulation and an autophagy flux blockade after sepsis, linked to reduced muscle mass and function. Pharmacologic induction of autophagy with urolithin A restored autophagy flux, mitochondrial respiration, and muscle phenotypes in vivo and in vitro, identifying a candidate therapy to mitigate post‑sepsis disability.
Impact: First demonstration that an autophagy flux blockade underpins long‑term muscle dysfunction after sepsis and identification of urolithin A as a pharmacologic rescue — bridges human omics to therapeutic proof‑of‑principle.
Clinical Implications: Motivates randomized trials of urolithin A in sepsis survivors to reduce post‑ICU disability and argues for inclusion of mitochondrial/autophagy biomarkers in rehabilitation strategies.
Key Findings
- Mitochondrial pathways remained dysregulated at 7 days and 6 months post‑ICU and correlated with muscle mass/function.
- Sepsis induced an autophagy flux blockade demonstrated by LC3B‑II/p62 and TEM; urolithin A restored autophagy flux and mitochondrial/muscle function in vivo and in vitro.